Report flags legal risks of AI-generated drug evidence

A Crowell & Moring client alert says probabilistic AI models in drug discovery can produce plausible-but-wrong outputs that affect regulatory submissions, trial integrity and legal liability. It lists five risks: hallucinations, unrepresentative training data, opaque reasoning, input sensitivity and adversarial manipulation of training data, and urges experimental validation, human oversight and preparation for FDA and EU guidance.

• EU bishops call for AI to serve the human person2026-10-19
• Analysis: terror networks exploit EU financial rules to evade detection2026-10-19
• AI Tool Tumor Site Risk Wins FDA Clearance2026-10-16
• Google fights EU bid to open Android to AI rivals2026-09-29
• Who Should Be Held Accountable When an AI Agent Acts Maliciously?2026-09-29